A Composite Probiotic Agent for the Improvement of Bacterial Vaginosis and Its Application

Abstract

This invention relates to a composite probiotic for improving bacterial vaginosis (BV), a probiotic agent, and its application. The composite probiotic comprises Lacticaseibacillus paracasei LC86 and Lacticaseibacillus rhamnosus LRa66. This combination can significantly balance vaginal pH, improve cytokine levels, and restore microbial diversity in the vaginal environment. The synergistic effect of the two strains enhances the therapeutic efficacy compared to individual strains.

Keywords

Bacterial Vaginosis, Probiotics, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, Vaginal Health

Introduction

Bacterial vaginosis (BV) is characterized by an imbalance of the normal vaginal flora, particularly a reduction in lactobacilli, leading to the overgrowth of harmful bacteria. Conventional antibiotic treatments have limitations such as high recurrence rates, potential disruption of normal flora, and antibiotic resistance. Probiotics, especially from the Lacticaseibacillus genus, offer a natural and safe alternative for restoring and maintaining vaginal microecological balance.

Materials and Methods

Composite Probiotic Strains

· Lacticaseibacillus paracasei LC86 (CGMCC No.1.12731)

· Lacticaseibacillus rhamnosus LRa66 (CGMCC No.24282)

Probiotic Agent Preparation

1. Activation and fermentation of LC86 and LRa66 strains.

2. Centrifugation of fermentation broth and mixing with cryoprotectants.

3. Lyophilization to produce LC86 and LRa66 powders.

4. LC86 and LRa66 blends in specified ratios to produce the composite probiotic agent.

Cryoprotectants

Cryoprotectants used include skim milk, gelatin, dextrin, arabic gum, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol, and xylitol.

Results

The composite probiotic significantly balanced the vaginal pH, optimized vaginal health status, improved cytokine levels, and restored the diversity of the vaginal microbiota. The synergistic interaction between LC86 and LRa66 enhanced these effects compared to individual strains.

Discussion

The study demonstrated that the combination of Lacticaseibacillus paracasei LC86 and Lacticaseibacillus rhamnosus LRa66 provides a superior therapeutic effect on bacterial vaginosis than either strain alone. The composite probiotic not only restores the vaginal microflora but also enhances the immune response and maintains a healthy vaginal environment.

Conclusion

The composite probiotic consisting of Lacticaseibacillus paracasei LC86 and Lacticaseibacillus rhamnosus LRa66 offers an effective, natural, and safe approach to improve bacterial vaginosis. Its application can be extended to various forms of probiotic agents, including lyophilized powders, capsules, tablets, and granules.